A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial

Background: high recurrence rates of up to 75% within 2 years in pancreatic ductal adenocarcinoma (PDAC) patients resected for cure indicate a high medical need for clinical prediction tools and patient specific treatment approaches. Addition of the EGFR inhibitor erlotinib to adjuvant chemotherapy...

Full description

Bibliographic Details
Main Authors: K. Hoyer, R. Hablesreiter, Y. Inoue, K. Yoshida, F. Briest, F. Christen, N. Kakiuchi, T. Yoshizato, Y. Shiozawa, Y. Shiraishi, J.K. Striefler, S. Bischoff, P. Lohneis, H. Putter, O. Blau, U. Keilholz, L. Bullinger, U. Pelzer, M. Hummel, H. Riess, S. Ogawa, M. Sinn, F. Damm
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:EBioMedicine
Subjects:
Pancreatic cancer
Precision medicine
Erlotinib
SMAD4
MAPK9
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396421001201

Similar Items

Similar Items